{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T12:52:05Z","timestamp":1764852725667,"version":"3.46.0"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T00:00:00Z","timestamp":1750291200000},"content-version":"vor","delay-in-days":169,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003787","name":"Natural Science Foundation of Hebei Province","doi-asserted-by":"publisher","award":["H2023206153"],"award-info":[{"award-number":["H2023206153"]}],"id":[{"id":"10.13039\/501100003787","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/j.lrr.2025.100523","type":"journal-article","created":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T19:11:34Z","timestamp":1750360294000},"page":"100523","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Selinexor combination with decitabine and half-dose CMG (Cytarabine+ Mitoxantrone+G-CSF) in Patients with refractory\/relapsed acute myeloid leukemia (AML) previously exposed to Venetoclax: a single-center retrospective study"],"prefix":"10.1016","volume":"24","author":[{"given":"Zi-Yu","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ya-Bei","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Ao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin-Hai","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Ling","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9981-049X","authenticated-orcid":false,"given":"Zi-Yuan","family":"Nie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lrr.2025.100523_bib0001","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.pharmthera.2015.06.001","article-title":"Expression, function, and targeting of the nuclear exporter chromosome region maintenance 1 (CRM1) protein","volume":"153","author":"Ishizawa","year":"2015","journal-title":"Pharmacol Ther"},{"issue":"Suppl 1","key":"10.1016\/j.lrr.2025.100523_bib0002","doi-asserted-by":"crossref","first-page":"S178","DOI":"10.1134\/S0006297922140140","article-title":"Targeting XPO1-dependent nuclear export in cancer","volume":"87","author":"Kim","year":"2022","journal-title":"Biochemistry (Mosc)"},{"issue":"10262","key":"10.1016\/j.lrr.2025.100523_bib0003","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0140-6736(20)32292-3","article-title":"Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial","volume":"396","author":"Grosicki","year":"2020","journal-title":"Lancet"},{"issue":"49","key":"10.1016\/j.lrr.2025.100523_bib0004","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000027884","article-title":"Efficacy and safety of selinexor in the treatment of AML: a protocol for systematic review and meta-analysis","volume":"100","author":"Yu","year":"2021","journal-title":"Medicine"},{"issue":"7","key":"10.1016\/j.lrr.2025.100523_bib0005","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00277-018-3304-y","article-title":"Salvage regimens using conventional chemotherapy agents for relapsed\/refractory adult AML patients: a systematic literature review","volume":"97","author":"Meg\u00edas-Vericat","year":"2018","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.lrr.2025.100523_bib0006","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/leu.2017.23","article-title":"Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure","volume":"31","author":"Wattad","year":"2017","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.lrr.2025.100523_bib0007","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9080972","article-title":"Hypomethylating agents (HMAs) as salvage therapy in relapsed or refractory AML: an Italian multicentric retrospective study","volume":"9","author":"Lessi","year":"2021","journal-title":"Biomedicines"},{"issue":"8","key":"10.1016\/j.lrr.2025.100523_bib0008","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1182\/bloodadvances.2018016121","article-title":"Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort","volume":"2","author":"Stahl","year":"2018","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.lrr.2025.100523_bib0009","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.lrr.2025.100523_bib0010","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov"},{"issue":"7","key":"10.1016\/j.lrr.2025.100523_bib0011","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24076816","article-title":"Azacitidine is synergistically lethal with XPO1 inhibitor selinexor in acute myeloid leukemia by targeting XPO1\/eIF4E\/c-MYC signaling","volume":"24","author":"Long","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.lrr.2025.100523_bib0012","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1080\/10428194.2019.1665664","article-title":"Selinexor in combination with decitabine in patients with acute myeloid leukemia: results from a phase 1 study","volume":"61","author":"Bhatnagar","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"10.1016\/j.lrr.2025.100523_bib0013","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.3324\/haematol.2017.185082","article-title":"Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial","volume":"103","author":"Zhang","year":"2018","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.lrr.2025.100523_bib0014","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13045-017-0550-8","article-title":"A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia","volume":"11","author":"Wang","year":"2018","journal-title":"J Hematol Oncol"}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048925000251?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048925000251?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T12:48:21Z","timestamp":1764852501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213048925000251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":14,"alternative-id":["S2213048925000251"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2025.100523","relation":{},"ISSN":["2213-0489"],"issn-type":[{"type":"print","value":"2213-0489"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selinexor combination with decitabine and half-dose CMG (Cytarabine+ Mitoxantrone+G-CSF) in Patients with refractory\/relapsed acute myeloid leukemia (AML) previously exposed to Venetoclax: a single-center retrospective study","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2025.100523","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100523"}}